The goal of IMPACT (Isotope and Muon Production using Advanced Cyclotron and Target technologies) is the construction of two new target stations and beamlines at the Paul Scherrer Institute’s (PSI) high-intensity proton accelerator HIPA to increase the available muon rates by up to a factor 100 for much improved experiments in particle physics and materials science (HIMB) and to create radioisotopes suitable for advanced cancer treatments in the required quantities for clinical studies (TATTOOS). As part of the project, complementary infrastructures at the University of Zurich (UZH) and at the University Hospital Zurich (USZ) are planned to fully exploit the potential of these new installations.
Scientific Highlights & News
Radiopharmacy: past, present and future
Radiopharmaceuticals allow some types of cancer to be targeted with tailor-made therapies. The current state of the art was preceded by decades of intensive research – and the future promises even better treatment options.
Taking the fear out of cancer
Researchers at PSI are developing new technologies and drugs to eliminate tumours more effectively: with greater precision and personalised approaches
Important funding for muon research
PSI gets an NCCR: The Muoniverse project will further expand research on the beamlines for elementary particles called muons – at the world’s leading facility for muon beams.